1
|
Veluswamy R, Bhalla S, Samstein R, Marron T, Gomez J, Doroshow D, Sabari J, Shum E, Saxena A, Namakydoust A, Chachoua A, Wisnivesky J, Mandeli J, Bhardwaj N, Hirsch F, Merad M, Reddy E. 1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Marron T, Maier B, LaMarche N, Hegde S, Belabed M, Mattiuz R, Hennequin C, LeBerichel J, Park M, Hall N, Ogrady D, Fitzgerald B, Gomez J, Doroshow D, Veluswamy R, Rolfo C, Smith C, Rohs N, Yankelevitz D, Chaddha U, Harkin T, Beasley M, Hirsch F, Merad M. P2.12-05 Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes with PD-L1 Blockade to Reverse Type-2Mediated Immunosuppression. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Merad M, Antoun S, Planchard D, Daoudi N, Hamza L, Scotté F. 1727P Factors associated with unplanned hospitalization among patients with lung cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Tai S, Remark R, Laface I, Del Valle DM, Torres J, Rahman A, Laird RM, Porter C, Riddle M, Murray JA, Choung R, Sato T, Plevy S, Merad M, Colombel J, Gnjatic S, Mortha A. A5 GM-CSF AUTOANTIBODIES: PREDICTORS OF CROHN’S DISEASE DEVELOPMENT AND A NOVEL THERAPEUTIC APPROACH. J Can Assoc Gastroenterol 2021. [DOI: 10.1093/jcag/gwab002.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Crohn’s disease (CD) is a heterogenous, chronic inflammatory disorder driven by a combination of genetic, environmental, and microbiota-dependent risk factors. Mononuclear phagocytes (MNP) are crucial cells that maintain intestinal homeostasis. An important cytokine for MNP survival and function is granulocyte-macrophage colony stimulating factor (GM-CSF). Interestingly, several studies reported CD-associated genetic risk variants within the GM-CSF receptor and its downstream signaling components. Furthermore, high titers of autoantibodies specific to GM-CSF can be detected in CD patients. Taken together, this data suggests an important role for GM-CSF in abrogation of CD development in a subgroup of patients.
Aims
This study sought to investigate the function of GM-CSF autoantibodies in CD.
Methods
We retrospectively quantified and characterized GM-CSF autoantibodies in sera of 220 CD, 200 ulcerative colitis (UC) patients, and 220 healthy controls (HC) sampled at 3 time points prior to disease diagnosis and one time point after diagnosis. ELISA was used to determine GM-CSF autoantibody titers and isotypes followed by in vitro multiplexed mass cytometry (CyTOF) neutralization assays on peripheral blood mononuclear cells. Flow cytometry and CyTOF were used to map the profile of immune cells isolated from inflamed and non-inflamed CD mucosa.
Results
Our data demonstrates that GM-CSF autoantibodies are specific to CD, significantly elevated up to 7 years prior to diagnosis of disease, and correlate with disease location, severity, and complications at the time of diagnosis. Moreover, in contrast to GM-CSF autoantibodies in pulmonary alveolar proteinosis patients, CD-associated autoantibodies neutralize GM-CSF via specific recognition of post-translational modifications (PTM), affecting MNP function. Removal of PTM enabled GM-CSF to escape autoantibody binding and restored MNP response to GM-CSF in the presence of neutralizing antibodies, indicating a potential therapeutic avenue. Furthermore, we identified group 3 innate lymphoid cells (ILC3) as a major source of GM-CSF in the healthy intestinal tract, suggesting intriguing crosstalk of MNP and ILC3 across the GM-CSF-GM-CSFR axis.
Conclusions
Our results identify GM-CSF autoantibodies as predictive serological biomarker for CD in a subgroup of patients presenting with severe and complicated form of disease at the time of diagnosis. The presence of GM-CSF autoantibodies precedes the onset of CD by several years and likely abrogates homeostatic immune cell crosstalk involving ILC3 and MNP, suggesting the development of a pre-diseased state in CD patients.
Funding Agencies
CIHRDr. Edward Ketchum Graduate Scholarship
Collapse
Affiliation(s)
- S Tai
- Immunology, University of Toronto, Toronto, ON, Canada
| | - R Remark
- Icahn School of Medicine Mount Sinai, New York, NY
| | - I Laface
- Icahn School of Medicine Mount Sinai, New York, NY
| | | | - J Torres
- Icahn School of Medicine Mount Sinai, New York, NY
| | - A Rahman
- Immunomonitoring Core at Mount Sinai, New York, NY
| | - R M Laird
- Naval Medical Research Center, Silver Spring, MD
| | - C Porter
- Naval Medical Research Center, Silver Spring, MD
| | - M Riddle
- Naval Medical Research Center, Silver Spring, MD
| | - J a Murray
- Gastroenterology, The Mayo Clinic, Rochester, MN
| | - R Choung
- Gastroenterology, The Mayo Clinic, Rochester, MN
| | - T Sato
- Janssen Research and Development LLC, Raritan, NJ
| | - S Plevy
- Janssen Research and Development LLC, Raritan, NJ
| | - M Merad
- Icahn School of Medicine Mount Sinai, New York, NY
| | - J Colombel
- Icahn School of Medicine Mount Sinai, New York, NY
| | - S Gnjatic
- Icahn School of Medicine Mount Sinai, New York, NY
| | - A Mortha
- Immunology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
5
|
Sun R, Achkar S, Ammari S, Bockel S, Douir N, Mevel G, Diop K, Corbin S, Hubert F, Brusadin G, Merad M, Laville A, Ka K, Bossi A, Rivera S, Chargari C, Deutsch E. 1675MO Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot. Ann Oncol 2020. [PMCID: PMC7506406 DOI: 10.1016/j.annonc.2020.08.1740] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, Balleyguier C, Besse B, Marabelle A, Netzer F, Merad M, Robert C, Barlesi F, Gachot B, Stoclin A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol 2020; 31:961-964. [PMID: 32247642 PMCID: PMC7136869 DOI: 10.1016/j.annonc.2020.03.300] [Citation(s) in RCA: 236] [Impact Index Per Article: 59.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 03/26/2020] [Accepted: 03/27/2020] [Indexed: 12/13/2022] Open
Affiliation(s)
- J-M Michot
- Department of Therapeutic Innovation and Early Testing.
| | - L Albiges
- Medical Oncology, University Paris Saclay, Gustave Roussy
| | - N Chaput
- Molecular Analysis, modélisation et imagerie de la Maladie cancéreuse, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, INSERM, CNRS
| | - V Saada
- Department of Biology, University Paris Saclay, Gustave Roussy
| | - F Pommeret
- Medical Oncology, University Paris Saclay, Gustave Roussy
| | - F Griscelli
- Department of Biology, University Paris Saclay, Gustave Roussy
| | | | - B Besse
- Medical Oncology, University Paris Saclay, Gustave Roussy
| | - A Marabelle
- Department of Therapeutic Innovation and Early Testing
| | - F Netzer
- Department of Pharmacy, Villejuif, France
| | - M Merad
- Medical Oncology, University Paris Saclay, Gustave Roussy
| | - C Robert
- Medical Oncology, University Paris Saclay, Gustave Roussy
| | - F Barlesi
- Medical Oncology, University Paris Saclay, Gustave Roussy
| | - B Gachot
- Intensive Care Department, Université Paris-Saclay, Gustave Roussy Villejuif, France
| | - A Stoclin
- Intensive Care Department, Université Paris-Saclay, Gustave Roussy Villejuif, France
| |
Collapse
|
7
|
Merad M, de Montalivet E, Legrand M, Mastinu E, Ortiz-Catalan M, Touillet A, Martinet N, Paysant J, Roby-Brami A, Jarrasse N. Assessment of an Automatic Prosthetic Elbow Control Strategy Using Residual Limb Motion for Transhumeral Amputated Individuals With Socket or Osseointegrated Prostheses. ACTA ACUST UNITED AC 2020. [DOI: 10.1109/tmrb.2020.2970065] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
8
|
Marron T, Leader A, Lavin Y, Maier B, Casanova-Acebes M, Wolf A, Flores R, Beasley M, Rahman A, Kenigsberg E, Merad M. IA13 Targeting Myeloid Cells that Define the Tumor Immune Microenvironment in NSCLC. J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2019.12.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Leader A, Maier B, Grout J, Chang C, Walker L, Davila M, Lanksy A, Marron T, Flores R, Beasley M, Salmon H, Rahman A, Kenigsberg E, Merad M. P2.04-04 CITEseq Characterization in Early Stage NSCLC Patients Identifies Distinct Patterns of Immune Infiltrate. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Marron T, Wolf A, Flores R, Veluswamy R, Gomez J, Beasley M, Yankelevitz D, Leader A, Lowy I, Miller E, Thurston G, Jankovic V, Deering R, Brown B, Rahman A, Gnjatic S, Hirsch F, Bhardwaj N, Merad M. EP1.04-15 NSCLC Response Determinants to Chemoimmunotherapy: Deep Profiling of Tumors Following Neoadjuvant Cemiplimab and Chemotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Merad M, de Montalivet E, Legrand M, Touillet A, Martinet N, Paysant J, Roby-Brami A, Jarrassé N. Improving the control of prostheses in arm amputees with approaches based on motor coordination. Comput Methods Biomech Biomed Engin 2019. [DOI: 10.1080/10255842.2020.1714976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- M. Merad
- CNRS, UMR 7222, ISIR/INSERM, U1150 Agathe-ISIR, Sorbonne University, Paris, France
| | - E. de Montalivet
- CNRS, UMR 7222, ISIR/INSERM, U1150 Agathe-ISIR, Sorbonne University, Paris, France
| | - M. Legrand
- CNRS, UMR 7222, ISIR/INSERM, U1150 Agathe-ISIR, Sorbonne University, Paris, France
| | - A. Touillet
- Institut Régional de Réadaptation, UGECAM Nord-est, Nancy, France
| | - N. Martinet
- Institut Régional de Réadaptation, UGECAM Nord-est, Nancy, France
| | - J. Paysant
- Institut Régional de Réadaptation, UGECAM Nord-est, Nancy, France
| | - A. Roby-Brami
- CNRS, UMR 7222, ISIR/INSERM, U1150 Agathe-ISIR, Sorbonne University, Paris, France
| | - N. Jarrassé
- CNRS, UMR 7222, ISIR/INSERM, U1150 Agathe-ISIR, Sorbonne University, Paris, France
| |
Collapse
|
12
|
Merad M, de Montalivet E, Lestoille M, Touillet A, Martinet N, Paysant J, Roby-Brami A, Jarrassé N. Using the body kinematics to assess the utilization of transhumeral prostheses. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Jarrasse N, Müller D, De Montalivet E, Richer F, Merad M, Touillet A, Martinet N, Paysant J. A simple movement based control approach to ease the control of a myoelectric elbow prosthetics in transhumeral amputees. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
14
|
Merad M, Alibay A, Ammari S, Antoun S, Bouguerba A, Ayed S, Vincent F. [Pulmonary tumor thrombotic microangiopathy]. Rev Mal Respir 2017; 34:1045-1057. [PMID: 29153757 DOI: 10.1016/j.rmr.2017.02.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 02/08/2017] [Indexed: 12/25/2022]
Abstract
Pulmonary tumor thrombotic microangiopathy syndrome is a rare clinicopathological entity in which tumor cell micro-emboli in the pulmonary microcirculation induced thrombotic microangiopathy. This can cause respiratory failure, and acute or sub-acute right heart failure. Histological features include micro tumor emboli in the small arteries and arterioles of the lung associated with thrombus formation and fibro-cellular and fibro-muscular intimal proliferation. The diagnosis is however extremely difficult to make before death. Thus, most of the observations reported are based on autopsy data. Very rare diagnostic observations made before death suggest the potential effectiveness of chemotherapy. Many details remain to be elucidated, interdisciplinary research is a priority with close collaboration between pathologists and clinicians to better understand this, often fatal, syndrome. It may be that the use of targeted therapies will improve the very poor prognosis allowing survival of several weeks or months after diagnosis.
Collapse
Affiliation(s)
- M Merad
- Service d'urgence en oncologie médicale, Gustave-Roussy Cancer Campus Grand Paris, Villejuif, 94805 Villejuif cedex, France
| | - A Alibay
- Service d'urgence en oncologie médicale, Gustave-Roussy Cancer Campus Grand Paris, Villejuif, 94805 Villejuif cedex, France
| | - S Ammari
- Service de radiologie, Gustave-Roussy Cancer Campus Grand Paris, Villejuif, 94805 Villejuif cedex, France
| | - S Antoun
- Service d'urgence en oncologie médicale, Gustave-Roussy Cancer Campus Grand Paris, Villejuif, 94805 Villejuif cedex, France
| | - A Bouguerba
- Réanimation polyvalente, GHIC Le-Raincy Montfermeil, 93370 Montfermeil, France
| | - S Ayed
- Réanimation polyvalente, GHIC Le-Raincy Montfermeil, 93370 Montfermeil, France
| | - F Vincent
- Réanimation polyvalente, GHIC Le-Raincy Montfermeil, 93370 Montfermeil, France.
| | | |
Collapse
|
15
|
Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry 2017; 7:e1065. [PMID: 28323284 PMCID: PMC5416674 DOI: 10.1038/tp.2017.31] [Citation(s) in RCA: 118] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Revised: 01/24/2017] [Accepted: 01/24/2017] [Indexed: 12/11/2022] Open
Abstract
A subset of patients with depression have elevated levels of inflammatory cytokines, and some studies demonstrate interaction between inflammatory factors and treatment outcome. However, most studies focus on only a narrow subset of factors in a patient sample. In the current study, we analyzed broad immune profiles in blood from patients with treatment-resistant depression (TRD) at baseline and following treatment with the glutamate modulator ketamine. Serum was analyzed from 26 healthy control and 33 actively depressed TRD patients free of antidepressant medication, and matched for age, sex and body mass index. All subjects provided baseline blood samples, and TRD subjects had additional blood draw at 4 and 24 h following intravenous infusion of ketamine (0.5 mg kg-1). Samples underwent multiplex analysis of 41 cytokines, chemokines and growth factors using quantitative immunoassay technology. Our a priori hypothesis was that TRD patients would show elevations in canonical pro-inflammatory cytokines; analyses demonstrated significant elevation of the pro-inflammatory cytokine interleukin-6. Further exploratory analyses revealed significant regulation of four additional soluble factors in patients with TRD. Several cytokines showed transient changes in level after ketamine, but none correlated with treatment response. Low pretreatment levels of fibroblast growth factor 2 were associated with ketamine treatment response. In sum, we found that patients with TRD demonstrate a unique pattern of increased inflammatory mediators, chemokines and colony-stimulating factors, providing support for the immune hypothesis of TRD. These patterns suggest novel treatment targets for the subset of patients with TRD who evidence dysregulated immune functioning.
Collapse
Affiliation(s)
- D D Kiraly
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA,Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA,Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - S R Horn
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - N T Van Dam
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - S Costi
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - J Schwartz
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - S Kim-Schulze
- The Immunology Institute, Human Immune Monitoring Core, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - M Patel
- The Immunology Institute, Human Immune Monitoring Core, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - G E Hodes
- Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - S J Russo
- Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - M Merad
- The Immunology Institute, Human Immune Monitoring Core, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - D V Iosifescu
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA,Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - D S Charney
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA,Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA,Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - J W Murrough
- Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA,Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA,Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY 10029, USA. E-mail:
| |
Collapse
|
16
|
Lanoy E, Antoun S, Iacovelli R, Loriot Y, Merad M, Massard C, Fizazi K, Dipalma M, Escudier B. Contribution of Tumor Burden and Body Composition Parameters As Prognostic Factors of Metastatic Renal Cell Carcinoma (Mrcc) Treated By Targeted Therapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Micol JB, Chahine C, Woerther PL, Ghez D, Netzer F, Dufour C, Merad M, Blot F, Chachaty E, de Botton S, Gachot B. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical? Clin Microbiol Infect 2014; 20:O453-5. [DOI: 10.1111/1469-0691.12445] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 10/11/2013] [Accepted: 11/02/2013] [Indexed: 11/30/2022]
|
18
|
Merad M, Soufi W, Ghalem S, Boukli F, Baig M, Ahmad K, Kamal M. Molecular Interaction of Acetylcholinesterase with Carnosic Acid Derivatives: A Neuroinformatics Study. CNSNDDT 2014; 13:440-6. [DOI: 10.2174/18715273113126660157] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/02/2013] [Revised: 05/17/2013] [Accepted: 06/02/2013] [Indexed: 11/22/2022]
|
19
|
Martin JCJ, Bériou G, Heslan M, Chauvin C, Utriainen L, Aumeunier A, Scott CL, Mowat A, Cerovic V, Houston SA, Leboeuf M, Hubert FX, Hémont C, Merad M, Milling S, Josien R. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol 2014; 7:101-13. [PMID: 23653115 PMCID: PMC4291114 DOI: 10.1038/mi.2013.28] [Citation(s) in RCA: 114] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2012] [Accepted: 04/08/2013] [Indexed: 02/04/2023]
Abstract
Interleukin-22 (IL-22) is mainly produced at barrier surfaces by T cells and innate lymphoid cells and is crucial to maintain epithelial integrity. However, dysregulated IL-22 action leads to deleterious inflammation and is involved in diseases such as psoriasis, intestinal inflammation, and cancer. IL-22 binding protein (IL-22BP) is a soluble inhibitory IL-22 receptor and may represent a crucial regulator of IL-22. We show both in rats and mice that, in the steady state, the main source of IL-22BP is constituted by a subset of conventional dendritic cells (DCs) in lymphoid and non-lymphoid tissues. In mouse intestine, IL-22BP was specifically expressed in lamina propria CD103(+)CD11b(+) DC. In humans, IL-22BP was expressed in immature monocyte-derived DC and strongly induced by retinoic acid but dramatically reduced upon maturation. Our data suggest that a subset of immature DCs may actively participate in the regulation of IL-22 activity in the gut by producing high levels of IL-22BP.
Collapse
Affiliation(s)
- JCJ Martin
- INSERM Center of Research in Transplantation and Immunology, UMR1064, Nantes, F - 44000, France,CHU Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F-44000, France,CHU Nantes, Laboratoire d’immunologie, Nantes, F-44000, France,Université de Nantes, Faculté de Médecine, Nantes, F-44000, France
| | - G Bériou
- INSERM Center of Research in Transplantation and Immunology, UMR1064, Nantes, F - 44000, France,CHU Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F-44000, France
| | - M Heslan
- INSERM Center of Research in Transplantation and Immunology, UMR1064, Nantes, F - 44000, France,CHU Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F-44000, France
| | - C Chauvin
- INSERM Center of Research in Transplantation and Immunology, UMR1064, Nantes, F - 44000, France,CHU Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F-44000, France
| | - L Utriainen
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
| | - A Aumeunier
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
| | - CL Scott
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
| | - A Mowat
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
| | - V Cerovic
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
| | - SA Houston
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
| | - M Leboeuf
- Department of Gene and Cell medicine and the Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
| | - FX Hubert
- INSERM Center of Research in Transplantation and Immunology, UMR1064, Nantes, F - 44000, France,CHU Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F-44000, France,Université de Nantes, Faculté de Médecine, Nantes, F-44000, France
| | - C Hémont
- INSERM Center of Research in Transplantation and Immunology, UMR1064, Nantes, F - 44000, France,CHU Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F-44000, France,CHU Nantes, Laboratoire d’immunologie, Nantes, F-44000, France,Université de Nantes, Faculté de Médecine, Nantes, F-44000, France
| | - M Merad
- Department of Gene and Cell medicine and the Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
| | - S Milling
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
| | - R Josien
- INSERM Center of Research in Transplantation and Immunology, UMR1064, Nantes, F - 44000, France,CHU Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F-44000, France,CHU Nantes, Laboratoire d’immunologie, Nantes, F-44000, France,Université de Nantes, Faculté de Médecine, Nantes, F-44000, France
| |
Collapse
|
20
|
Baliram R, Chow A, Huber AK, Collier L, Ali MR, Morshed SA, Latif R, Teixeira A, Merad M, Liu L, Sun L, Blair HC, Zaidi M, Davies TF. Thyroid and bone: macrophage-derived TSH-β splice variant increases murine osteoblastogenesis. Endocrinology 2013; 154:4919-26. [PMID: 24140716 PMCID: PMC3836071 DOI: 10.1210/en.2012-2234] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
It is now firmly established that TSH may influence the physiology and patho-physiology of bone by activating osteoblasts and inhibiting osteoclast activity resulting in relative osteoprotection. Whether this influence is directly exerted by pituitary-derived TSH in vivo is less certain, because we have previously reported that the suppression of pituitary TSH does not remove such protection. Here, we have characterized the functional relevance of a novel form of the TSH-β subunit, designated TSH-βv, known to be produced by murine bone marrow cells. We found that fresh bone marrow-derived macrophages (MØs) preferentially produced TSH-βv and, when cocultured with CHO cells engineered to overexpress the full-length TSH receptor, were able to generate the production of intracellular cAMP; a phenomenon not seen in control CHO cells, such results confirmed the bioactivity of the TSH variant. Furthermore, cocultures of MØs and osteoblasts were shown to enhance osteoblastogenesis, and this phenomenon was markedly reduced by antibody to TSH-β, suggesting direct interaction between MØs and osteoblasts as observed under the electron microscope. These data suggest a new paradigm of local modulation of bone biology by a MØ-derived TSH-like molecule and raise the question of the relative contribution of local vs pituitary-derived TSH in osteoprotection.
Collapse
Affiliation(s)
- R Baliram
- Room 2F-28, James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York, NY 10468.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Merad M, Chachaty E, Gachot B, Alibay A, Dipalma M, Sami A. Epidemiology, Resistance Profile and Origin of Bacteremia in Non-Neutropenic Patients with Solid Tumor. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34103-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
22
|
Antoun S, Albiges L, Iacovelli R, Martin L, Loriot Y, Merad M, Fizazi K, Baracos V, Escudier B. O55 Impact des thérapies ciblées en cancérologie sur la masse musculaire et le tissu adipeux. NUTR CLIN METAB 2011. [DOI: 10.1016/s0985-0562(11)70059-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
23
|
Albiges L, Antoun S, Martin L, Merad M, Loriot Y, Baracos V, Escudier BJ. Effect of everolimus therapy on skeletal muscle wasting in patients with metastatic renal cell carcinoma (mRCC): Results from a placebo-controlled study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.319] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
319 Background: We have previously reported that sorafenib induces muscle wasting in mRCC (Antoun, JCO 2010). As everolimus exerts its antineoplastic through inhibition of the mammalian target of rapamycin (mTOR), a key element of intracellular signalling of protein synthesis in skeletal muscle, we hypothesized that muscle wasting would be also an important side effect of everolimus therapy. Methods: All patients with mRCC enrolled in RECORD 1 (everolimus (E) or placebo (P) post TKI failure) in IGR (n=40) were analyzed for this study. Patients were eligible if at least 2 CT scans were available. CT image analysis, which has high precision and specificity for evaluation of specific muscles, was used to define change in total skeletal muscle. The third lumbar vertebra (L3) was chosen as a landmark. Images were analyzed using Slice-O-Matic software V4.3 (Tomovision). Tissue Hounsfield unit thresholds were employed: −29 to +150 for skeletal muscle. Subsequently, tissue cross-sectional areas (cm2) were computed. Results: 35 patients (83% male, median age 60y) were evaluable, 10 on P and 25 on E. In addition, 9 patients initially on P could cross to E (as per protocol) and were analyzed both on P and on E. Median durations of treatment were 79 and 263 days respectively on P and E. Placebo patients had stable body weight, with no significant mean gain or loss of muscle. By contrast, patients on E lost body weight over time: −2.5±3.6 kg by 83 d (p=0.02), −4.9±5.7 (p=0.005) by 167 d and –5.0±7.6 kg (p=0.02) by 286 d. E patients progressively lost skeletal muscle compared .with baseline from −2.5±5.9% at 83d (p=0.06), to −4.0±7.5% at 167d (p=0.03) and −4.8±6.8% at 263d (p=0.01). Interstingly, the 9 patients who had maintained body weight (+2.0 kg) and muscle (+2.7%) whilst on placebo, and crossed to E, promptly lost weight (−4.8 kg, p<0.03) and skeletal muscle (−5.3%) (about 1.5 kg of muscle) when crossed to E. Conclusions: Body weight and muscle wasting are induced by everolimus in mRCC, and are not related to progressive disease. These changes increase over time. Relation between these changes and outcome will be presented at the meeting. [Table: see text]
Collapse
Affiliation(s)
- L. Albiges
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, Villejuif, France; Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - S. Antoun
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, Villejuif, France; Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - L. Martin
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, Villejuif, France; Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - M. Merad
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, Villejuif, France; Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - Y. Loriot
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, Villejuif, France; Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - V. Baracos
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, Villejuif, France; Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - B. J. Escudier
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, Villejuif, France; Department of Oncology, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
24
|
Borget I, Antoun S, Bonnet P, Gachot B, Chachaty E, Di Palma M, Merad M. Outpatient management in febrile neutropenia with an intermediary risk of complications: Limitative clinical factors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Ginhoux F, Ng LG, Merad M. Understanding the murine cutaneous dendritic cell network to improve intradermal vaccination strategies. Curr Top Microbiol Immunol 2010; 351:1-24. [PMID: 21058006 DOI: 10.1007/82_2010_115] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
Dendritic cells (DCs) form a heterogeneous group of antigen presenting cells that play different roles in tissue immunity. Recent studies have revealed the presence of distinct DC populations in murine skin, highlighting the complexity of the cutaneous DC network. In this review, we will define the major DC subsets that populate the different layers of the skin, focusing on their origin and the mechanisms controlling their homeostasis. We will also review recent evidence underlining the functional specialization of dermal DC subsets and its relevance in the design of novel vaccine approaches.
Collapse
Affiliation(s)
- F Ginhoux
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A STAR), 8A Biomedical Grove, Immunos, Biopolis, Singapore 138648, Singapore.
| | | | | |
Collapse
|
26
|
Gachot B, Radu I, Merad M, Laouira S, Souffi C, Chachaty E. F-08 Bactériémies nosocomiales à Staphylococcus lugdunensis et S. schleiferi en onco-hématologie : étude préliminaire. Med Mal Infect 2008. [DOI: 10.1016/s0399-077x(08)73119-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
Antoun S, Merad M, Raynard B, Ruffie P. [Evaluating the nutritional status of a lung cancer patient is an important element in patient management]. Rev Pneumol Clin 2008; 64:92-98. [PMID: 18589290 DOI: 10.1016/j.pneumo.2008.03.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Nutritional status assessment during the comprehensive management of patients treated for cancer is becoming increasingly necessary. Various data are currently available which show a relationship between the nutritional status and certain morbidity-mortality parameters. In contrast, there is a paucity of data concerning lung cancer. A relationship between survival and the nutritional status has been found in the literature, exclusively in advanced stages of lung cancer. Unlike that observed in oncological digestive tract surgery, where artificial nutrition is recommended preoperatively in severely malnourished patients, no link has been evidenced between postoperative morbidity and mortality and the preoperative nutritional status in lung surgery. The scientific nutritional societies simply recommend preoperative nutritional assessment. Reflection on management of malnourished patients receiving chemotherapy is still "archaic" and recent studies and recommendations are lacking. Although largely prescribed, oral nutritional supplements have not proven efficient and patient compliance will probably have to be improved. According to "good nutrition practice" rules, the digestive tube should be used when it is functional and in theory, enteral nutrition is indicated in this situation. In addition to the lack of clinical studies, one of the obstacles to its use is cultural with the need to obtain not only patient approval but also that of the prescriber. Parenteral nutrition was discredited in earlier studies. It should probably be reevaluated in the context of new chemotherapeutic molecules and a different way of handling nutrition care. The physiological concept of omega-3 fatty acid modulation of inflammation is of interest in animal studies but the clinical modalities of use remain to be defined and determined. The role of nutrition in the management of lung cancer is still very limited but there are major expectations and many solutions are awaited in the coming years.
Collapse
Affiliation(s)
- S Antoun
- Service des Urgences, Institut Gustave-Roussy, 39 Rue Camille-Desmoulins, 94805 Villejuif Cedex, France.
| | | | | | | |
Collapse
|
28
|
Haniffa M, Ginhoux F, Abel M, Bullock S, Alshemali S, Merad M, Collin M. 376: Persistent Recipient Antigen-Presenting Cells in Human Hematopoietic Stem Cell Transplantation: Identification of a Dermal Subset that Outlives Epidermal Langerhans Cells. Biol Blood Marrow Transplant 2008. [DOI: 10.1016/j.bbmt.2007.12.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Abstract
Hematopoietic stem cell transplantation is an important experimental tool and therapeutic modality. Its efficacy and toxicity are both linked to a GvH reaction that is initiated by donor T cells recognizing recipient APC, of which DC are the most potent. In most tissues recipient DC are replaced after transplantation because they turnover rapidly from BM-derived precursors. However, in a number of sites, notably the skin, recipient DC may persist and even self-renew for many months after transplantation. Understanding the homeostasis of different APC populations and how they are related to the induction of alloreactivity may help to improve the therapeutic benefit of transplantation.
Collapse
Affiliation(s)
- M P Collin
- Department of Gene and Cell Medicine, Mount Sinai Medical School, New York, New York 10029, USA.
| | | | | |
Collapse
|
30
|
Couzigou C, Mazeron MC, Escaut L, Merad M, Vittecoq D. [Valganciclovir maintenance therapy in AIDS: treatment failure due to the development of cytomegalovirus resistance to ganciclovir]. Med Mal Infect 2005; 35:98-100. [PMID: 15780901 DOI: 10.1016/j.medmal.2004.11.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2004] [Accepted: 11/24/2004] [Indexed: 11/24/2022]
Affiliation(s)
- C Couzigou
- Service de maladies infectieuses, hôpital Paul-Brousse, 12, avenue Paul-Vaillant-Couturier, 94804 Villejuif, France
| | | | | | | | | |
Collapse
|
31
|
Adam O, Merad M, Antoun S, Bourhis JH, Gachot B, Casiraghi O, Chachaty E. [Usefulness of panfungal PCR for the diagnosis of fungal infection in immunocompromised patients]. ACTA ACUST UNITED AC 2005; 52:544-9. [PMID: 15531120 DOI: 10.1016/j.patbio.2004.07.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2004] [Accepted: 07/21/2004] [Indexed: 11/24/2022]
Abstract
The diagnostic of invasive fungal infection is often difficult because of the low sensitivity of fungal culture from infected tissues. Here we have assessed the ability of a panfungal PCR targeted on the DNA region encoding the RNA genes followed by sequencing of the amplification products to detect and identify fungi from tissue biopsies. This assay allowed us to identify the microorganism responsible for an invasive fungal infection in three of our patients. In two cases, hepatosplenic candidiasis was suspected and Candida albicans DNA was detected from liver biopsies. The third patient was cared for a thymome and developed a manubrium osteitis caused by Scedosporium apiospermum.
Collapse
Affiliation(s)
- O Adam
- Pôle microbiologie et maladies infectieuses, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France.
| | | | | | | | | | | | | |
Collapse
|
32
|
Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Rozenbaum W, Naït-Ighil L, Nguyen TH, Slama L, Girard PM, Molina JM, Sereni D, Colin de Verdière N, Lascoux-Combes C, Pintado C, Ponscarme D, Prevoteau de Clary F, Tourneur M, Bentata M, Guillevin L, Launay O, Mansouri R, Rouges F, Kazatchkine M, Aouba A, Azizi M, Fiessinger JN, Le Houssine P, Sicard D, Bernasconi C, Salmon D, Silbermann B, Cassuto JP, Ceppi C, Poiree D, Raguin G, Merad M, Delfraissy JF, Goujard C, Quertainmont Y, Perronne C, de Truchis P, Dupont B, Bresson JL, Calatroni I, Raffi F, Esnault JL, Leautez S. Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure. Antivir Ther 2004. [DOI: 10.1177/135965350400900407] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objectives To compare the antiviral efficacy of a salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple anti-retroviral regimens had failed. Design Phase IIb, randomized, open-label, multicentre trial. Patients were eligible if they had <500 CD4+ cells/mm3 and >4 log10 copies/ml HIV-RNA after treatment with at least two protease inhibitors (PIs) and one non-nucleoside reverse transcriptase inhibitor. Results At baseline ( n=37), the median CD4+ cell count was 207/mm3 and the median plasma HIV-1 RNA level was 4.7 log10 copies/ml; the median number of PI mutations was seven and the median decrease in phenotypic susceptibility to lopinavir and amprenavir was 9.7 and 2.6, respectively. The mean number of antiretrovirals received prior to randomization was 7.7. The fall in the median HIV-1 RNA level at week 26 was -1.4 log10 copies/ml in the 200 mg/d ritonavir group and -2.5 log10 copies/ml in the 400 mg/d group ( P=0.02). Viral load fell below 50 copies/ml in 32% and 61% of patients, respectively ( P=0.07). After adjustment for the ritonavir dose, a smaller number of PI mutations was the only baseline characteristic associated with a better virological response at week 26. Amprenavir concentrations were significantly lower in presence of lopinavir. The lopinavir inhibitory quotient at week 6 correlated weakly with the change in the HIV-RNA level at week 26. Conclusion Combination of amprenavir, lopinavir and 400 mg/d ritonavir shows significant virological efficacy without increased toxicity in HIV-infected patients in whom multiple antiretroviral regimens have failed.
Collapse
Affiliation(s)
| | - Gilles Raguin
- Service de Maladies Infectieuses, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France
- Departement de Medecine, Hôpital Croix-St-Simon, Paris, France
| | - Geneviève Chêne
- Inserm U593, Université Victor Segalen Bordeaux 2, Bordeaux, France
| | | | | | - Cécile Droz
- Inserm U593, Université Victor Segalen Bordeaux 2, Bordeaux, France
| | - Clotilde Le Tiec
- Service de Pharmacie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - François Clavel
- Inserm U552, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Pierre-Marie Girard
- Service de Maladies Infectieuses, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - A Aouba
- Hôpital Européen Georges Pompidou, Paris
| | - M Azizi
- Hôpital Européen Georges Pompidou, Paris
| | | | | | | | | | | | | | | | | | | | - G Raguin
- Hôpital de la Croix Saint Simon Paris
| | - M Merad
- Hôpital de la Croix Saint Simon Paris
| | | | - C Goujard
- Hôpital de Bicêtre Le Kremlin-Bicêtre
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
The prognosis of HIV infection has been modified by antiretroviral therapy. However, the morbidity and the mortality of HCV co-infection increase and may be a major problem of health service. Up to now co-infected patients are excluded of transplantation due to complexity, the ethical aspects, the immunodeficiency and the co-infection. This study tries to estimate the feasibility in this population. Between December 1999 and March 2002, seven patients were transplanted. The average of CD4 was 332/ml; the viral load was <50 copies/ml. Before transplantation, no patient had experienced opportunist infection and all patients received antiretroviral therapy adapted to their history. The average follow-up is of 14 months: one patient died 3 months after transplantation, the other one presented a candida in oesophagus, the average of CD4 was 280/ml, and viral load was <50 copies/ml in five patients. A relapse of HVC was observed in all patients. Interferon/rivabirine therapy was proposed for four patients. Every patient received tacrolimus and corticoids. HAART were modified four times for toxicity and one time for virological failure. We observed two cases of transient renal insufficiency, two cases of diabetes, two cases of pancreatitis, and abnormalities of the respiratory mitochondrial chain in four patients. Finally, liver transplantation in HIV-HCV co-infected patients seems to be feasible when strict criteria of selection are taken into account. This still experimental strategy requires a multidisciplinary partnership.
Collapse
Affiliation(s)
- D Vittecoq
- Service des maladies infectieuses, hôpital Paul-Brousse, 12-14, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France.
| | | | | | | | | | | |
Collapse
|
34
|
Guermazi A, Feger C, Rousselot P, Merad M, Benchaib N, Bourrier P, Mariette X, Frija J, de Kerviler E. Granulocytic sarcoma (chloroma): imaging findings in adults and children. AJR Am J Roentgenol 2002; 178:319-25. [PMID: 11804886 DOI: 10.2214/ajr.178.2.1780319] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- A Guermazi
- Department of Radiology, Saint-Louis Hospital, AP-HP, 1 ave Claude Vellefaux, 75010 Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Merad M, Mesurolle B, Guinebretière JM, Lecesne A, Missenard G, Vanel D. Recurrence of a primary malignant giant cell tumour of bone 14 years after initial surgery. Eur Radiol 2002; 11:1483-6. [PMID: 11519561 DOI: 10.1007/s003300000796] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Giant cell tumour (GCT) is usually considered a benign entity. A small fraction of these tumours become malignant with time, and an extremely rare fraction may be malignant at onset. We report herein an unusual case of primary malignant GCT of the bone that relapsed locally with the same histology 14 years after a simple surgical curettage.
Collapse
Affiliation(s)
- M Merad
- Department of Medicine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Dendritic cells (DCs) are professional antigen-presenting cells which both initiate adaptive immune responses and control tolerance to self-antigens. It has been suggested that these different effects on responder cells depend on subsets of DCs arising from either myeloid or lymphoid hematopoietic origins. In this model, CD8 alpha+ Mac-1- DCs are supposed to be of lymphoid while CD8 alpha- Mac-1+ DCs are supposed to be of myeloid origin. Here we summarize our findings that both CD8 alpha+ and CD8 alpha- DCs can arise from clonogenic common myeloid progenitors (CMPs) in both thymus and spleen. Therefore CD8 alpha expression DCs does not indicate a lymphoid origin and differences among CD8 alpha+ and CD8 alpha- DCs might rather reflect maturation status than ontogeny. On the basis of transplantation studies, it seems likely that most of the DCs in secondary lymphoid organs and a substantial fraction of thymic DCs are myeloid-derived.
Collapse
Affiliation(s)
- M G Manz
- Department of Pathology and Developmental Biology, B261 Beckman Center, Stanford University School of Medicine, 279 Campus Drive, Stanford, California 94305-5428, USA.
| | | | | | | | | | | | | |
Collapse
|
37
|
Mesurolle B, Merad M, Ariche M, Mignon F, Goumot PA. In the heart of radiology, for valentine's day. AJR Am J Roentgenol 2001; 176:525-7. [PMID: 11159108 DOI: 10.2214/ajr.176.2.1760525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- B Mesurolle
- Department of Radiology, Institut Gustave-Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif Cedex, France
| | | | | | | | | |
Collapse
|
38
|
Abstract
Dendritic cells (DCs) are critical in both initiating adaptive immune responses and maintaining tolerance to self antigens. These apparently contradictory roles have been suggested to depend on different subsets of DCs that arise from either myeloid or lymphoid hematopoietic origins, respectively. Although DC expression of CD8alpha is attributed to a lymphoid origin, here we show that both CD8alpha+ and CD8alpha- DCs can arise from clonogenic common myeloid progenitors in both thymus and spleen. Thus, expression of CD8alpha is not indicative of a lymphoid origin, and phenotypic and functional differences among DC subsets are likely to reflect maturation status rather than ontogeny.
Collapse
Affiliation(s)
- D Traver
- Department of Pathology, Stanford University, Stanford, CA 94305, USA
| | | | | | | | | | | | | |
Collapse
|
39
|
Monsuez JJ, Gallet B, Escaut L, Vayre F, Charniot JC, Pulik M, Merad M, Minozzi C, Slama M, Weber S, Vittecoq D. Clinical outcome after coronary events in patients treated with HIV-protease inhibitors. Eur Heart J 2000; 21:2079-80. [PMID: 11102259 DOI: 10.1053/euhj.2000.2264] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
40
|
Merad M, Fong L, Bogenberger J, Engleman EG. Differentiation of myeloid dendritic cells into CD8alpha-positive dendritic cells in vivo. Blood 2000; 96:1865-72. [PMID: 10961888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
Bone marrow-derived dendritic cells (DC) represent a family of antigen-presenting cells (APC) with varying phenotypes. For example, in mice, CD8alpha(+) and CD8alpha(-) DC are thought to represent cells of lymphoid and myeloid origin, respectively. Langerhans cells (LC) of the epidermis are typical myeloid DC; they do not express CD8alpha, but they do express high levels of myeloid antigens such as CD11b and FcgammaR. By contrast, thymic DC, which derive from a lymphoid-related progenitor, express CD8alpha but only low levels of myeloid antigens. CD8alpha(+) DC are also found in the spleen and lymph nodes (LN), but the origin of these cells has not been determined. By activating and labeling CD8alpha(-) epidermal LC in vivo, it was found that these cells expressed CD8alpha on migration to the draining LN. Similarly, CD8alpha(-) LC generated in vitro from a CD8 wild-type mouse and injected into the skin of a CD8alphaKO mouse expressed CD8alpha when they reached the draining LN. The results also show that CD8alpha(+) LC are potent APC. After migration from skin, they localized in the T-cell areas of LN, secreted high levels of interleukin-12, interferon-gamma, and chemokine-attracting T cells, and they induced antigen-specific T-cell activation. These results demonstrate that myeloid DC in the periphery can express CD8alpha when they migrate to the draining LN. CD8alpha expression on these DC appears to reflect a state of activation, mobilization, or both, rather than lineage. (Blood. 2000;96:1865-1872)
Collapse
Affiliation(s)
- M Merad
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
| | | | | | | |
Collapse
|
41
|
Abstract
With the advent of helical CT, the capability of noninvasive imaging of the thoracic aorta has been enhanced considerably. In this article, we describe the potential of helical CT using dual-slice technology to evaluate thoracic aortic diseases such dissection, aneurysm, trauma, infection, inflammation, thromboembolic disease, and postoperative complications. Technical considerations for optimal CT imaging as well as limitations of helical CT are highlighted.
Collapse
Affiliation(s)
- B Mesurolle
- Department of Radiology, University René Descartes, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | | | | | | | | | | |
Collapse
|
42
|
Monsuez JJ, Gallet B, Escaut L, Vayre F, Pulik M, Charniot JC, Merad M, Slama M, Weber S, Vittecoq D. [Cardiac side effects of anti-HIV agents]. Arch Mal Coeur Vaiss 2000; 93:835-40. [PMID: 10975035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Both nature and prognosis of cardiac complications occurring in patients infected by the Human Immunodeficiency Virus-1 (HIV-1) have changed considerably since the introduction of highly acive and anti-retroviral triple therapy ("HART"). Opportunist cardiac infections have thus been displaced and side effects of drugs now occupy the primary aetiological role. Torsades de pointe may be exceptionally triggered by anti-infectious agents such as pentacarinat or trimethoprime-sulfamethoxazole, as are those induced by the association of ketoconazole and terfenadine or cisapride, the dangers of which are well known and the prevention more effective, especially with the association with HIV antiproteases which inhibit the cytochrome P450. The diagnosis of iatrogenic myocardial dysfunction is more difficult, except when it occurs acutely as with phosphonoformate (Foscarnet), or interleukine-2. Progressive cardiomyopathy caused by -interferon and dideoxynucleosides (zidovudine, didanosine and zalcitabine), reversible on withdrawal of the drug responsible in half the cases, should be distinguished from those due to the HIV itself (therapeutic relay) or to another associated cause (alcohol, coronary artery disease). The coronary complications of diseases treated by antiproteases usually occur in smokers whose cholesterol and triglyceride levels are rapidly increased with HAART. In a series of 9 patients (amongst 700 treated with the antiproteases), after the acute phase of myocardial infarction during which the interventional approach is often preferred, the medium-term prognosis is relatively good, on condition that the patients correct the hyperlipidaemia and give up smoking.
Collapse
Affiliation(s)
- J J Monsuez
- Service de médecine interne, hôpital Paul-Brousse, Villejuif
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Merad M, Angevin E, Wolfers J, Flament C, Lorenzi I, Triebel F, Escudier B, Zitvogel L. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12). J Immunother 2000; 23:369-78. [PMID: 10838666 DOI: 10.1097/00002371-200005000-00010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The combination of interferon-alpha (IFN-alpha) plus interleukin (IL-2) has been accepted in the treatment of metastatic renal cell carcinoma (MRCC), whereas vaccines based on IL-12 or dendritic cells (DCs) are still being investigated. Here the authors analyzed 1) the feasibility to generate functional monocyte-derived DCs (MDDCs) from patients treated with biological response modifiers (BRMs) who have MRCC, 2) the phenotypic modulations of these MDDCs during BRM treatment. Eight and 13 MRCC patients received IL-2 plus IFN-alpha or IL-12 immunotherapy, respectively. The adherent fraction of mononuclear cells from patients' blood drawn before, during, and after immunotherapy was incubated in clinically approved culture medium supplemented with 5% autologous serum, rhu granulocyte macrophage colony-stimulating factor, and rhuIL-4 for a week. At day 7 or 8 of culture, floating cells were examined in flow cytometric and functional assays (alloreactivity, proliferation assays in the presence of tetanus toxoid or tumor peptides, IL-12 secretion). In all patients except two, MDDCs could be generated but at a lower rate compared with healthy volunteers. Morphologic and phenotypical analyses revealed immature DCs with low levels of CD1a or CD83 expression throughout therapy with BRMs. Capacities in mixed leukocyte reactions were similar to those of healthy volunteers and stable during immunotherapy, whereas presentation of major histocompatibility complex class II tetanus toxoid peptide complexes was slightly enhanced during and after IL-12 therapy. IL-12 expression levels under IFN-gamma and CD40L stimulation were significantly lower in MDDC cultures from patients with MRCC compared with healthy volunteers. Overall, peripheral blood mononuclear cells from a cohort of 21 patients with metastatic disease who were treated with BRMs maintained their ability to differentiate into functional MDDCs with no selective quantitative or qualitative advantage.
Collapse
Affiliation(s)
- M Merad
- Unité d'Immunothérapie, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Radiation therapy is used to treat many intrathoracic and chest wall malignancies. A variety of changes may occur after radiation therapy to the thorax. Radiation therapy produces dramatic effects in the lung. Pulmonary necrosis is an uncommon, severe, late complication of adjuvant postoperative radiation therapy. Bronchiolitis obliterans with organizing pneumonia is a distinct clinicopathologic entity characterized by patchy, migratory, peripheral air-space infiltrates. Radiation therapy can also cause spontaneous pneumothorax, mesothelioma, and lung cancer. In the mediastinum, radiation therapy may cause thymic cysts, calcified lymph nodes, and esophageal injuries. Cardiovascular complications of radiation therapy are often delayed and insidious. Premature coronary artery stenosis occurs after radiation therapy to the mediastinum. Radiation therapy may also give rise to calcifications of the ascending aorta, pericardial disease, valvular injuries, and conduction abnormalities. Women who undergo thoracic irradiation before the age of 30 years have a high risk of developing a second breast cancer. Radiation-induced sarcomas are an infrequent but well-recognized complication of radiation therapy. Other chest wall injuries due to radiation therapy are osteochondroma and rib or clavicle fractures. Knowledge of the imaging features of injuries caused by radiation therapy can prevent misinterpretation as recurrent tumor and may facilitate further treatment.
Collapse
Affiliation(s)
- B Mesurolle
- Department of Radiology, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Mesurolle B, Qanadli SD, Merad M, Mignon F, Lacombe P, Dubourg O. Anomalous origin of the left coronary artery arising from the pulmonary trunk: report of an adult case with long-term follow-up after surgery. Eur Radiol 1999; 9:1570-3. [PMID: 10525866 DOI: 10.1007/s003300050885] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
An anomalous origin of the left coronary artery arising from the pulmonary artery is a congenital malformation rarely described in adults. We report the case of a 65-year-old patient with this anomaly. Clinical presentation, imaging identification (coronary angiogram, MRI and electron-beam CT), surgical treatment and angiographic long-term follow-up are described.
Collapse
Affiliation(s)
- B Mesurolle
- Department of Radiology, Hôpital Ambroise Paré, 9 avenue Charles de Gaulle, F-92104 Boulogne-Billancourt Cedex, France
| | | | | | | | | | | |
Collapse
|
46
|
Affiliation(s)
- M Merad
- Department of Medicine, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | |
Collapse
|
47
|
Soria JC, Fizazi K, Merad M, Le Chevalier T. [Inappropriate antidiuretic hormone secretion disclosing a second primary lung cancer 5 years after complete remission of a small cell lung carcinoma]. Bull Cancer 1996; 83:605-8. [PMID: 8869039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We report the case of a female patient who developed a second contralateral small cell lung carcinoma (SCLC) five years after a right upper lobe SCLC treated by sequential chemotherapy and chest radiation therapy. This second primary neoplasia was revealed by an isolated and symptomatic syndrome of inappropriate antidiuretic hormone secretion. Specific evolution of long-term survivors after SCLC are discussed, including consequences of combined radiochemotherapy and poor prognosis associated with persistence of tobacco smoking exposure.
Collapse
Affiliation(s)
- J C Soria
- Département de médecine, institut Gustave-Roussy, Villejuif, France
| | | | | | | |
Collapse
|